Bionomics Limited

Equities

BNOX

US09063M2052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1 ^USD	+3.49%		+2.10%	-32.43%

Mar. 21	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI
Mar. 15	Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023

November 28, 2023 at 06:03 am EST

Bionomics Limited announced that Dr. Errol De Souza will not be standing for re-election to the Company's Board of Directors at the upcoming Annual General Meeting (AGM) on November 30, 2023, which retirement from the Board will be effective as of the AGM. Following Dr. De Souzas retirement from the Board of Directors, it will be now composed of a total of 6 Directors. Errol has been a valuable long-standing member of the Board for over 15 years, added Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics.

Latest news about Bionomics Limited

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	Mar. 21	CI
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 15	CI
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data	Jan. 22	MT
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap	Jan. 22	MT
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023	Nov. 28	CI
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	Nov. 10	DJ
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA	23-10-16	MT
Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting Meeting with the U.S. Food and Drug Administration	23-10-16	CI
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session	23-10-03	MT
Top Premarket Gainers	23-10-02	MT
Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-29	CI
Bionomics Retreats 15% Premarket Friday After Surging 244% in Previous Trading Session Following Positive Phase 2b Data	23-09-29	MT
Bionomics Sinks 12% After Hours Thursday Following 244% Surge in Previous Regular Trading Session on Positive Phase 2b Trial Results	23-09-28	MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-28	MT
Top Midday Gainers	23-09-28	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-09-28	MT
Sector Update: Health Care	23-09-28	MT
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	23-09-28	MT
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	23-09-28	MT
Sector Update: Health Care Stocks Gain Premarket Thursday	23-09-28	MT
Sector Update: Health Care	23-09-28	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28	MT
Bionomics Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms	23-09-28	MT
Top Premarket Gainers	23-09-28	MT
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	23-09-28	CI

Chart Bionomics Limited

Duration

Period

More charts

Company Profile

Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the Î±7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its Î±7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimerâs disease and other central nervous system conditions. The Companyâs CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bionomics Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.533 AUD

Average target price

15.3 AUD

Spread / Average Target

+897.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONOMICS LIMITED	-32.43%	10.69M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs